These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18652233)

  • 1. [Progenotoxic shift in mammary adipose tissue (adipogenotoxicosis): association with clinical and biological characteristics of breast cancer].
    Bershtein LM; Kovalevskiĭ AIu; Poroshina TE; Revskoĭ SIu; Kotov AV; Kovalenko IG; Tsyrlina EV; Semiglazov VF; Turkevich EA; Pozharisskiĭ KM
    Vopr Onkol; 2008; 54(3):294-302. PubMed ID: 18652233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Properties of mammary fat in breast cancer patients: topographic, systemic and environmental factors].
    Bershteĭn LM; Kovalevskiĭ AIu; Poroshina TE; Kovalenko IG; Kotov AV; Semenov II; Pozharisskiĭ KM
    Vopr Onkol; 2007; 53(5):515-20. PubMed ID: 18154112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormonal and progenotoxic properties of mammary fat in pre- and postmenopausal cancer patients].
    Bershteĭn LM; Kotov AV; Kovalevskiĭ AIu; Poroshina TE; Kovalenko IG; Tsyrlina EV; Semiglazov VF; Pozharisskiĭ KM
    Vopr Onkol; 2006; 52(5):505-10. PubMed ID: 17168356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia.
    Berstein LM; Kovalevskij AY; Poroshina TE; Kotov AV; Kovalenko IG; Tsyrlina EV; Leenman EE; Revskoy SY; Semiglazov VF; Pozharisski KM
    Int J Cancer; 2007 Aug; 121(3):514-9. PubMed ID: 17397026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogenic microenvironment generated by organochlorine residues in adipose mammary tissue modulates biomarker expression in ERalpha-positive breast carcinomas.
    Muñoz-de-Toro M; Durando M; Beldoménico PM; Beldoménico HR; Kass L; García SR; Luque EH
    Breast Cancer Res; 2006; 8(4):R47. PubMed ID: 16859517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease.
    Roubicek T; Bartlova M; Krajickova J; Haluzikova D; Mraz M; Lacinova Z; Kudla M; Teplan V; Haluzik M
    Nutrition; 2009; 25(7-8):762-8. PubMed ID: 19539174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
    Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of low repair efficiency with high hormone receptors expression and SOD activity in breast cancer patients.
    Agnoletto MH; Guecheva TN; Dondé F; de Oliveira AF; Franke F; Cassini C; Salvador M; Henriques JA; Saffi J
    Clin Biochem; 2007 Nov; 40(16-17):1252-8. PubMed ID: 17915203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat.
    Bebenek M; Duś D; Koźlak J
    Adv Med Sci; 2008; 53(1):49-53. PubMed ID: 18614439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.
    Yigit E; Gönüllü G; Yücel I; Turgut M; Erdem D; Cakar B
    Eur J Intern Med; 2008 Dec; 19(8):602-7. PubMed ID: 19046726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of obesity on breast cancer development.
    Cleary MP; Grossmann ME; Ray A
    Vet Pathol; 2010 Mar; 47(2):202-13. PubMed ID: 20124008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor tissue aromatase and estrogen levels versus clinical course of endometrial cancer].
    Bersteĭn LM; Chernobrovkina AE; Gamaiunova VB; Vasil'ev DA; Kovalevskiĭ AIu; Maksimov SIa; Chepik OF; Gershfel'd ED
    Vopr Onkol; 2003; 49(1):55-9. PubMed ID: 12715371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.